Sam Fazeli

I did my maths in the comparison things, which of course is not head to head.

And then I'll go and take the sections of,

the keynote, was it 42-year patients and tried to make comparisons, which looked really good, I have to say, on small numbers of patients.

pbr1 expression uh is very encouraging obviously it's more data set but yes you can you can even in the um 1249 i was i was interested in i did i did a little comparison to keynote 42 by taking just the patients that had no prior therapy in your data set and that looked that looked from an orr perspective better um we'll see yeah again i think one of the things that we're seeing with um

Perhaps I should focus on the 10% plus or 20% plus or whatever.

We'll see, right?

Susan, it's exactly one hour.

Thank you very much for your time.

It's always a pleasure talking to you.

We can keep going for hours, of course, as I said.

But thank you for making the time.

Congratulations again on a fantastic ESMO.

And look forward to ASCO, although we have a whole bunch of other conferences in between.

Thank you for your time, Susan, again.